Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.Pastor, R.M., Burch, J.D., Magnuson, S., Ortwine, D.F., Chen, Y., De La Torre, K., Ding, X., Eigenbrot, C., Johnson, A., Liimatta, M., Liu, Y., Shia, S., Wang, X., Wu, L.C., Pei, Z.
(2014) Bioorg Med Chem Lett 24: 2448-2452
- PubMed: 24767842
- DOI: https://doi.org/10.1016/j.bmcl.2014.04.023
- Primary Citation of Related Structures:
4PP9, 4PPA, 4PPB, 4PPC
- PubMed Abstract:
There is evidence that small molecule inhibitors of the non-receptor tyrosine kinase ITK, a component of the T-cell receptor signaling cascade, could represent a novel asthma therapeutic class. Moreover, given the expected chronic dosing regimen of any asthma treatment, highly selective as well as potent inhibitors would be strongly preferred in any potential therapeutic. Here we report hit-to-lead optimization of a series of indazoles that demonstrate sub-nanomolar inhibitory potency against ITK with strong cellular activity and good kinase selectivity. We also elucidate the binding mode of these inhibitors by solving the X-ray crystal structures of the complexes.
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States. Electronic address: email@example.com.